Continuing the theme from our previous blog on the benefits of competition among prescription drugs, we now turn to another type of competition: the role of biosimilars in lowering the escalating prices of biologic drugs.
For America’s pharmacy benefit managers, PBMs, our core mission is to increase access to affordable prescription drugs for all Americans.
To analyze the role public policy plays in this challenge, host JC Scott talks with Lauren Aronson, health policy expert and Executive Director of the Campaign for Sustainable Rx Drug Pricing (CSRxP).
PCMA released a series of videos showcasing the value PBMs provide employers.
PBMs have distinct business processes that differentiate them in the market, but PBMs also adhere to stringent accreditation standards, the terms of negotiated contracts, and legal requirements.
Learn MoreJuly 20, 2021
(Washington, D.C.) — As the “National Call-In Day” takes place...
Keep ReadingJuly 13, 2021
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today...
Keep ReadingJuly 23, 2021
There is a growing sense among lawmakers the Biden administration's $1.2 trillion bipartisan infrastructure deal will move toward legislation, despite...
Keep ReadingJuly 23, 2021
The Senate Judiciary Committee will consider proposed legislation next week aiming to ban patent settlement deals that delay market entry...
Keep Reading
PCMA believes that organizational and employee success require a diverse, equitable, and inclusive workforce and a culture that embraces and encourages different perspectives. We recognize the inherent value in employing a workforce with a range of experiences and it is our commitment to embrace every person’s uniqueness and to provide a professional work environment where everyone is welcome and treated with dignity and respect.
PCMA has signed on to the CEO Action for Diversity & Inclusion™ pledge. Read more here.
